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Abstract: Isoniazid (INH) monotherapy has gained widespread acceptance as an efficacious therapy for latent tuberculosis infection
(LTBI) especially in low-prevalence settings. Although INH related hepatotoxicity is well recognized, progression to severe liver
dysfunction requiring care at a transplant center remains unpredictable. We report the management of a five year-old girl who developed
progressive liver failure due to INH prophylaxis. This highlights the potential severity of INH related hepatic injury and underscores the
significance of vigilant clinical monitoring throughout the duration of the therapy in children.
Keywords: isoniazid, hepatotoxicity, latent tuberculosis infection

Clinical Medicine Insights: Pediatrics 2011:5 9–13
doi: 10.4137/CMPed.S6406
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Pediatrics 2011:5

9

Desrochers et al

Introduction

Tuberculosis is a major global public health problem
affecting millions of new cases each year. A significant proportion the new cases, especially in lowprevalence settings such as seen in affluent countries
result from the reactivation of latent tuberculosis
infection (LTBI). Individuals with LTBI are typically asymptomatic, have normal chest radiograph,
but have a positive purified protein derivative (PPD)
skin test. A variety of treatment regimens have been
evaluated for the management of LTBI, with the aim
of reducing the likelihood of subsequent reactivation of tuberculosis. Isoniazid (INH) is currently
considered the most appropriate therapy in children
with LTBI.1 Although INH related hepatotoxicity is
well recognized, the burden of severe liver dysfunction requiring liver transplantation due to this therapy in children remains obscure given the lack of
studies in this population. Moreover, development
of liver failure can occur even with the discontinuation of INH at the onset of symptoms of liver dysfunction.2 Therefore, documentation of such cases
is a vital step to enhancing our comprehension of
how to manage a given patient with liver failure due
to INH therapy. Similarly, careful analysis of theses
cases may have a significant impact on the evolution
of certain aspects of guidelines for LTBI management in children.
Herein, we report a five year-old girl who developed progressive hepatic failure associated with INH
prophylaxis for LTBI. Liver histology was consistent with drug-induced injury and the patient favorably responded to supportive care and corticosteroid
therapy. This case highlights the potential severity of
INH related hepatic injury and underscores the significance of vigilant clinical monitoring throughout
the duration of the therapy in children.

Case Report

A previously healthy five year-old Hispanic female
presented with a three week history of progressive
anorexia and jaundice. At the time of presentation,
she had only three days left to complete a nine-month
course of isoniazid (INH) monotherapy for a positive PPD skin test and a normal chest radiograph performed at the local health department. She was born
in the United States but spent several months with her
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family in Mexico one year before PPD testing. The
patient received oral INH and vitamin B6 (25 mg)
twice weekly by directly observed therapy. She
reported to clinic each month for follow-up, and her
initial oral 350 mg INH dose was increased to 400 mg
twice weekly six months after initiation of therapy to
adjust for weight. Apart from Echinacea and multi
vitamins, no over the counter medications were given
during the prescribed INH therapy. A few days prior
to hospitalization, comprehensive metabolic panel at
a local clinic revealed an aspartate aminotransferase
(AST) of 2929 U/L, alanine transaminase (ALT) of
1941 U/L (normal , 45 for both), and total bilirubin
of 20.5 mg/dL (normal , 0.8 mg/dL). At the time of
hospitalization, the patient had marked conjuntival icterus and dermal jaundice but she was afebrile and had
no acute distress. Physical findings were otherwise
normal except for a mildly distended, non-tender
abdomen and hepatomegaly with a liver edge palpable four centimeters below the right costal margin at
the mid-clavicular line on inspiration. The spleen was
not enlarged and there were no cutaneous stigmata
of chronic liver disease. Neurologically, the patient
had normal mental status, strength, tone, and deep
tendon reflexes. Initial laboratory analysis showed
albumin 3.6 mg/dL (4.0–5.3 g/dL), alkaline phosphatase 399 U/L (130–560 U/L), AST 3485 U/L (normal 5–45 U/L), ALT 2327 (normal 5–45)U/L, GGT
48 U/L (normal 5–24 U/L), ammonia 45 µmol/L
(normal 17–68 µmol/L), PT 26.1 seconds (normal
10.1–12 seconds), and PTT 47.7 seconds (normal
26–36 seconds). Hepatitis A, B and C virus, cytomegalovirus and human immunodeficiency virus serology,
alpha-1 antitrypsin and ceruloplasmin concentrations, antinuclear, smooth-muscle and liver-kidneymicrosomal antibodies and chest radiograph yielded
negative-normal results. Results of Epstein-Barr virus
serology were consistent with past infection. She
developed progressive pruritis despite ursodeoxycholic acid therapy [total bilirubin 24.6 mg/dL, direct
bilirubin 15.6 mg/dL (0 to 0.4 mg/dL)] and remained
mildly coagulopathic (PT 16.1 seconds) despite daily
intravenous vitamin K. Attempted transjugular liver
biopsy was unsuccessful and she was transferred for
formal liver transplant evaluation. Histological examination of liver tissue obtained by laparoscopy showed
lymphoplasmacytic infiltration in portal, interface and
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lobular areas, with hepatic architectural collapse, fibrosis and severe cholestasis. These histological abnormalities were consistent with drug induced injury
and systemic corticosteroids were therefore started.
Within a few days, her overall condition including
coagulopathy and liver tests improved and she was

discharged home. The corticosteroids were gradually weaned over the next four months. Liver size and
biochemical profile normalized over this time. Six
months after discontinuing corticosteroids, the patient
was clinically well and without residual liver dysfunction (Fig. 1).
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Figure 1. Course of selected laboratory tests depicted over time. Pannel A) Prothrombin time; B) alanine aminotransferase; and C) total bilirubin. Arrow
indicates initiation of corticosteroid therapy.
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Discussion

Centers for Disease Control and Prevention (CDC)
recommends that children with LTBI should be
treated with INH prophylaxis for 9 months as a daily
self-administered therapy at a dose of 10–20 mg/kg
(maximum dose 300 mg) or twice weekly directly
observed therapy at a dose of 20–40 mg/kg (maximum
dose 900 mg). These recommendations are accessible
through CDC web page,3 which aim to not only cure the
individual patient, but also minimize the transmission
of Mycobacterium tuberculosis to healthy populations.
Indeed due to the public health perspective, CDC
takes a vigorous stand for the successful completion
of INH therapy. Whereas this therapy is generally well
tolerated with excellent results, the development of
significant liver dysfunction is well known in pediatric patients.2,4–8 We report this case to: a) underscore
the significance of optimal clinical monitoring, and
a timely cessation of therapy in the event of significant hepatoctoxicity; and b) to review the literature
on severe liver dysfunction due to INH prophylaxis to
ascertain if a common theme can be formulated for the
identification and management of such cases.
Consistent with previously reported pediatric cases
of INH-induced hepatotoxicity, the reasons for the severity of liver damage in our patient are unclear. History,
clinical examination and laboratory evaluation provided
no evidence of prior chronic liver disease and excluded
other potential causes for liver disease. Whether or
not Echinacea contributed to the hepatic insult in our
patient is not known. Being a non-regulated dietary
supplement, there is inadequate published data about
the significance of Echinacea in liver injury. Similarly,
younger age of our patient is also an unlikely contributor,
because, INH-related liver dysfunction has been most
often sited in adult population, although this may be at
least partly due to a reporting bias. Similarly, continued
use of INH for three weeks after the onset of progressive anorexia and jaundice prior to her presentation at
the local health department may have significantly contributed to the liver injury. Although liver injury was
noted to follow a chronic disease model (evident from
liver biopsy), one can postulate that discontinuation of
therapy three weeks earlier in her treatment might have
averted progression to hepatic failure. Indeed similar reports of INH administration beyond the onset of
hepatitis symptoms have been documented in children
as the most likely reason for severe liver injury.7,9 This
12

underscores the importance of appropriate training of
the workers for direct observational therapy and educating the family about what to look for and what to
do if symptoms of hepatotoxicity develop. In addition
to allied health care workers and physicians prescribing INH for LTBI should, apart from clinical monitoring, ensure that parental education is reinforced at each
monthly visit.10 By the same token, in the case of nonEnglish speaking families (such as the case presented
here), the caregivers should be provided a summary
of possible adverse effects, written in their native language along with specific instructions to follow in the
event toxicity occurs. Because severe hepatotoxicity
and death have been documented with continued INH
therapy after the onset hepatitis,9 the emphasis of the
education should be on cessation of this drug at the very
onset of symptoms of liver disease.
Similar to our case, at least thirteen children have
been reported to undergo evaluation for orthotopic liver
transplantation (OLT) due to INH-related hepatotoxicity
indicating severe liver injury due to this therapy.2,4–8 For
example, Wu et al, through a survey of liver transplantation centers described 10 patients who required OLT
due with INH-associated hepatic failure. In addition,
this study reported that six children died as a result of
INH hepatotoxicity without receiving a transplant.2
Similar reports of significant morbidity and mortality
due to INH associated liver injury have been made by
others.11–13 Apart from the monitoring issues discussed
above, collectively, these reports raise the question of
whether there any clinical or biochemical determinants
of severe liver dysfunction, and if so, how to utilize
these determinants to avoid significant morbidity and
mortality for a given patient. Unfortunately, the pathogenesis of INH-related liver injury remains elusive,
precluding the development of INH-hepatotoxicityprediction models. Therefore, a priori forecasting about
who will be at risk to develop severe INH-relate liver
injury remains insuperable at the moment. However,
INH-related hepatotoxicity is believed to be mediated
by mono-acetyl hydrazine, a metabolite of INH which is
activated by Cytochrome P-450 (CYP) enzyme system,
and detoxified by N-acetyltransferase-2.14 The activity
of both of these enzymes is well known to be influenced by genetic variability. For example, a constellation comprised of slow acetylator status coupled with
CYP 2E1 genetic polymorphism is known to be a risk
for INH related hepatotoxici.15 Similarly, concomitant
Clinical Medicine Insights: Pediatrics 2011:5
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administration of rifampicin, a CYP-450 inducer, can
significantly increase the risk of liver injury due to
INH.16,17 Although these insights are important for
understanding the basis of liver injury, due to substantial
costs, routine assessment of CYP 2E1 polymorphism or
N-acetyltransferase-2 activity is not feasible. Therefore,
to prevent acute or sub-acute liver failure due to INH,
the emphasis remains on early detection of INH related
hepatitis and avoiding concurrent administration of
other hepatotoxic drugs such as rifampicin.
In summary, INH therapy for LTBI prophylaxis in
children has been the standard of care for many years.
Given the burden of active tuberculosis and a well
accepted therapeutic appeal of INH for LTBI, any drastic amendments to decrease the duration of therapy are
unlikely. Most children with subclinical hepatic damage recover completely while continuing INH therapy.
However, due to poorly understood mechanisms, some
patients may develop significant liver injury requiring
care at a center with resources to perform liver transplantation. Early recognition and cessation of INH
therapy is necessary to prevent the progression of subclinical liver injury to liver failure. This report illustrates the significance of appropriate education of the
health care workers and the family and vigilant clinical
monitoring throughout the duration of the therapy.
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